- Home
- IMRN vs CERO Comparison
IMRN vs CERO Comparison
Compare IMRN & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMRN
- CERO
- Stock Information
- Founded
- IMRN 1994
- CERO 2017
- Country
- IMRN Australia
- CERO United States
- Employees
- IMRN N/A
- CERO N/A
- Industry
- IMRN Biotechnology: Pharmaceutical Preparations
- CERO
- Sector
- IMRN Health Care
- CERO
- Exchange
- IMRN Nasdaq
- CERO Nasdaq
- Market Cap
- IMRN 15.0M
- CERO 12.2M
- IPO Year
- IMRN N/A
- CERO N/A
- Fundamental
- Price
- IMRN $1.81
- CERO $0.29
- Analyst Decision
- IMRN Strong Buy
- CERO
- Analyst Count
- IMRN 1
- CERO 0
- Target Price
- IMRN $5.00
- CERO N/A
- AVG Volume (30 Days)
- IMRN 6.2K
- CERO 174.9M
- Earning Date
- IMRN 11-26-2024
- CERO 11-25-2024
- Dividend Yield
- IMRN N/A
- CERO N/A
- EPS Growth
- IMRN N/A
- CERO N/A
- EPS
- IMRN N/A
- CERO N/A
- Revenue
- IMRN $3,271,194.00
- CERO N/A
- Revenue This Year
- IMRN N/A
- CERO N/A
- Revenue Next Year
- IMRN N/A
- CERO N/A
- P/E Ratio
- IMRN N/A
- CERO N/A
- Revenue Growth
- IMRN 171.67
- CERO N/A
- 52 Week Low
- IMRN $1.59
- CERO $0.06
- 52 Week High
- IMRN $5.96
- CERO $12.80
- Technical
- Relative Strength Index (RSI)
- IMRN 35.96
- CERO 73.26
- Support Level
- IMRN $1.73
- CERO $0.17
- Resistance Level
- IMRN $1.99
- CERO $0.33
- Average True Range (ATR)
- IMRN 0.12
- CERO 0.04
- MACD
- IMRN 0.02
- CERO 0.02
- Stochastic Oscillator
- IMRN 20.42
- CERO 57.68
About IMRN Immuron Limited
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.